Galeterone

TargetMol
Product Code: TAR-T6509
Supplier: TargetMol
CodeSizePrice
TAR-T6509-5mg5mg£112.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6509-1mL1 mL * 10 mM (in DMSO)£117.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6509-10mg10mg£134.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6509-25mg25mg£185.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6509-50mg50mg£266.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6509-100mg100mg£389.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6509-200mg200mg£547.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Galeterone is an orally bioavailable small-molecule androgen receptor modulator and CYP17 lyase inhibitor with potential antiandrogen activity. Galeterone exhibits three distinct mechanisms of action: 1) as an androgen receptor antagonist, 2) as a CYP17 lyase inhibitor and 3) by decreasing overall androgen receptor levels in prostate cancer tumors, all of which may result in a decrease in androgen-dependent growth signaling. Localized to the endoplasmic reticulum (ER), the cytochrome P450 enzyme CYP17 (P450C17 or CYP17A1) exhibits both 17alpha-hydroxylase and 17, 20-lyase activities, and plays a key role in the steroidogenic pathway that produces progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens.
CAS:
851983-85-2
Formula:
C26H32N2O
Molecular Weight:
388.555
Pathway:
Metabolism; Endocrinology/Hormones
Purity:
0.9957
SMILES:
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2n1cnc2ccccc12
Target:
P45; Androgen Receptor

References

Schayowitz A, et al. Mol Cancer Ther, 2008, 7(1), 121-132. Bruno RD, et al. Mol Cancer Ther, 2008, 7(9), 2828-2836. Vasaitis T, et al. Mol Cancer Ther, 2008, 7(8), 2348-2357. Handratta VD, et al. J Med Chem, 2005, 48(8), 2972-2984. Schayowitz A, et al. Br J Cancer, 2010, 103(7), 12001-12007.